Go Pro
→ The cat is out the bag (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
$31.83
-0.5%		$30.79
$3.59
▼
$37.48
$1.26B1.13447,769 shs453,305 shs
Harrow, Inc. stock logo
HROW
Harrow
$34.07
-1.2%		$40.09
$28.54
▼
$54.85
$1.29B0.24462,948 shs524,034 shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$35.94
+0.9%		$35.37
$28.25
▼
$60.08
$1.45B0.46227,166 shs258,358 shs
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
$3.65
$3.65
$2.76
▼
$6.65
$381.02M0.93.78 million shsN/A
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-0.56%-10.71%-0.96%+51.36%+720.20%
Harrow, Inc. stock logo
HROW
Harrow
-1.19%-11.60%-14.89%-11.28%-13.57%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
+0.90%-6.04%+4.60%+12.77%-9.29%
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
$31.83
-0.5%		$30.79
$3.59
▼
$37.48
$1.26B1.13447,769 shs453,305 shs
Harrow, Inc. stock logo
HROW
Harrow
$34.07
-1.2%		$40.09
$28.54
▼
$54.85
$1.29B0.24462,948 shs524,034 shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$35.94
+0.9%		$35.37
$28.25
▼
$60.08
$1.45B0.46227,166 shs258,358 shs
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
$3.65
$3.65
$2.76
▼
$6.65
$381.02M0.93.78 million shsN/A
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-0.56%-10.71%-0.96%+51.36%+720.20%
Harrow, Inc. stock logo
HROW
Harrow
-1.19%-11.60%-14.89%-11.28%-13.57%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
+0.90%-6.04%+4.60%+12.77%-9.29%
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
2.64
Moderate Buy$37.2517.02% Upside
Harrow, Inc. stock logo
HROW
Harrow
2.67
Moderate Buy$66.3894.82% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.25
Hold$47.6732.63% Upside
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest RVNC, PAHC, HROW, and ANRO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/11/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C+)
9/9/2026
Harrow, Inc. stock logo
HROW
Harrow
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$45.00
9/9/2026
Harrow, Inc. stock logo
HROW
Harrow
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
9/9/2026
Harrow, Inc. stock logo
HROW
Harrow
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$45.00
8/20/2026
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/17/2026
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$50.00 ➝ $55.00
8/13/2026
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$24.00 ➝ $26.00
8/13/2026
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$28.00 ➝ $37.00
8/11/2026
Harrow, Inc. stock logo
HROW
Harrow
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
8/11/2026
Harrow, Inc. stock logo
HROW
Harrow
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$63.00
7/29/2026
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 9/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/AN/AN/AN/A$4.87 per shareN/A
Harrow, Inc. stock logo
HROW
Harrow
$275.59M4.63$0.85 per share39.89$1.41 per share24.16
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.52B0.96$4.61 per share7.79$9.50 per share3.78
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
$234.04M1.63N/AN/A($1.73) per share-2.11
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-$63.24M-$2.42N/AN/AN/AN/A-46.46%-39.09%11/11/2026 (Estimated)
Harrow, Inc. stock logo
HROW
Harrow
-$5.14M-$1.00N/A15.63N/A-13.51%-38.00%-3.37%11/9/2026 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$99.72M$2.4414.739.611.036.57%37.86%9.18%11/4/2026 (Estimated)
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
-$323.99M-$1.93N/AN/AN/A-74.67%N/A-37.22%N/A

Latest RVNC, PAHC, HROW, and ANRO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/26/2026Q4 2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.7130$0.85+$0.1370$0.53$381.18 million$396.75 million
8/12/2026Q2 2026
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-$0.7345-$0.65+$0.0845-$0.65N/AN/A
8/10/2026Q2 2026
Harrow, Inc. stock logo
HROW
Harrow
-$0.1788-$0.46-$0.2813-$0.46$70.35 million$70.66 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/AN/AN/AN/AN/A
Harrow, Inc. stock logo
HROW
Harrow
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.34%N/A19.67%N/A
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
N/AN/AN/AN/AN/A

Latest RVNC, PAHC, HROW, and ANRO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/28/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.121.2%9/2/20269/2/20269/23/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
0.07
14.85
14.85
Harrow, Inc. stock logo
HROW
Harrow
19.70
2.24
2.08
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.84
2.96
1.27
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
N/A
4.12
3.05

Institutional Ownership

CompanyInstitutional Ownership
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/A
Harrow, Inc. stock logo
HROW
Harrow
72.76%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
97.70%

Insider Ownership

CompanyInsider Ownership
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
11.25%
Harrow, Inc. stock logo
HROW
Harrow
12.80%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
50.13%
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
5.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
6839.24 million34.83 millionN/A
Harrow, Inc. stock logo
HROW
Harrow
37337.49 million32.69 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2,60540.60 million20.25 millionOptionable
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
500104.39 million99.07 millionNo Data

Recent News About These Companies

REVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
September 9, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/09/3147408/0/en/revance-alert-bragar-eagel-squire-p-c-is-investigating-revance-therapeutics-inc-on-behalf-of-long-term-stockholders-and-encourages-investors-to-contact-the-firm.html
Revance Names New CEO to Drive Next Phase in Aesthetic Innovation
May 23, 2025  |  globalcosmeticsnews.comG
Revance Announces Leadership Succession Plan to Support Next Phase of Growth and Innovation
May 21, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/revance-announces-leadership-succession-plan-200000684.html
Crown Laboratories Now Operates Under the Name Revance
March 31, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/crown-laboratories-now-operates-under-135900632.html
Johnson City-based Crown Labs now operating as ‘Revance’
March 31, 2025  |  wjhl.comW
REVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
March 6, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/07/3038722/0/en/revance-alert-bragar-eagel-squire-p-c-is-investigating-revance-therapeutics-inc-on-behalf-of-long-term-stockholders-and-encourages-investors-to-contact-the-firm.html
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors - Contact Levi & Korsinsky
March 4, 2025  |  accessnewswire.comA
Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - RVNC
March 4, 2025  |  accessnewswire.comA
RVNC DEADLINE TODAY: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important March 4 Deadline in Securities Class Action – RVNC
March 4, 2025  |  accessnewswire.comA
Contact Levi & Korsinsky by March 4, 2025 Deadline to Join Class Action Against Revance Therapeutics, Inc. (RVNC)
March 4, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/04/3036820/3080/en/contact-levi-korsinsky-by-march-4-2025-deadline-to-join-class-action-against-revance-therapeutics-inc-rvnc.html
Contact Levi & Korsinsky by March 4, 2025 Deadline to Join Class Action Against Revance Therapeutics, Inc. (RVNC)
March 4, 2025  |  accessnewswire.comA
Revance Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNC
March 4, 2025  |  accessnewswire.comA
FINAL REMINDER RVNC DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Revance Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit
March 4, 2025  |  accessnewswire.comA
Investors who lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNC
March 4, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investors-who-lost-money-on-revance-therapeutics-incrvnc-should-contact-levi--korsinsky-about-pending-class-action---rvnc-302390881.html
Investors who lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNC
March 3, 2025  |  accessnewswire.comA
March 4, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RVNC
March 3, 2025  |  accessnewswire.comA
RVNC DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important March 4 Deadline in Securities Class Action – RVNC
March 3, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/03/3036116/673/en/rvnc-deadline-tomorrow-rosen-national-investor-counsel-encourages-revance-therapeutics-inc-investors-to-secure-counsel-before-important-march-4-deadline-in-securities-class-action-.html
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) - March 4, 2025 Deadline to Join - Contact Levi & Korsinsky
March 3, 2025  |  accessnewswire.comA
Deadline Soon: Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
March 3, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250303520006/en/Deadline-Soon-Revance-Therapeutics-Inc.-RVNC-Investors-Who-Lost-Money-Urged-To-Contact-The-Law-Offices-of-Frank-R.-Cruz-About-Securities-Fraud-Lawsuit/
Revance Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – RVNC
March 3, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/03/3035916/0/en/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alto Neuroscience stock logo

Alto Neuroscience NYSE:ANRO

$31.83 -0.17 (-0.53%)
Closing price 09/14/2026 03:59 PM Eastern
Extended Trading
$32.04 +0.21 (+0.67%)
As of 04:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Harrow stock logo

Harrow NASDAQ:HROW

$34.07 -0.41 (-1.19%)
Closing price 09/14/2026 04:00 PM Eastern
Extended Trading
$33.86 -0.21 (-0.63%)
As of 04:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$35.94 +0.32 (+0.90%)
Closing price 09/14/2026 04:00 PM Eastern
Extended Trading
$35.92 -0.02 (-0.07%)
As of 09/14/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Revance Therapeutics stock logo

Revance Therapeutics NASDAQ:RVNC

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas